Overcoming Delivery Barriers and High Costs of SMA Therapeutics with Next-Generation Biomaterials
Background
Spinal Muscular Atrophy (SMA) is a rare genetic disorder where muscles gradually atrophy due to the degeneration of spinal anterior horn motor neurons. It is caused by a deficiency in the essential SMN (Survival Motor Neuron) protein due to a loss of the SMN1 gene. While treatments were previously limited to conservative management like respiratory support, the introduction of gene-targeted therapies has significantly increased patient survival rates.
Currently, standard treatments follow three paths. The antisense oligonucleotide (ASO) Nusinersen promotes protein production by inducing SMN2 splicing. Onasemnogene abeparvovec, based on the Adeno-Associated Virus (AAV) type 9 vector, is a replacement therapy that directly introduces a normal gene. The oral small-molecule compound Risdiplam is also widely prescribed.
However, existing therapies have shown limitations in in vivo delivery efficiency and durability. ASOs cannot cross the blood-brain barrier (BBB), requiring repeated intrathecal lumbar punctures throughout a patient's life. For patients with severe spinal deformities, frequent spinal injections cause extreme physical pain. Viral vectors cost billions of won per single dose, and additional dosing is impossible due to the formation of neutralizing antibodies, alongside risks of liver toxicity. This creates a demand for new drug carriers that can increase delivery efficiency and reduce the burden on patients.
Key Findings
This review article analyzes the pathophysiology of SMA and systematically examines research on biomaterial drug delivery to overcome the limitations of existing drugs. Researchers presented nanoparticles and biodegradable hydrogel systems as alternatives to supplement the drawbacks of viral vectors and reduce invasive procedures.
A prominent achievement is the development of surface-modified nanocarriers that cross the blood-brain barrier. Lipid nanoparticles (LNPs) conjugated with Apolipoprotein E (ApoE) or transferrin receptor ligands induce receptor-mediated endocytosis. Preclinical data confirmed that drugs can reliably reach spinal anterior horn motor neurons through intravenous injection alone. This result demonstrates that nucleic acid drugs can be delivered to target areas of the central nervous system without viral shells.
Local sustained-release hydrogel technology is also identified as a major solution. Hydrogels made of biocompatible polymers are designed to release a constant concentration of ASOs around the spinal canal over several months. This opens the possibility of extending the treatment interval from every three or four months to over half a year.
A multi-drug co-loading strategy is also noteworthy. SMN expression enhancers and Brain-Derived Neurotrophic Factor (BDNF) were loaded together inside the nanomaterials. This simultaneously drove SMN protein replenishment and neuromuscular junction (NMJ) reconstruction, further accelerating the rate of motor function recovery.
Implications and Outlook
This research shows that the treatment of rare diseases is evolving beyond molecular target searching into biomaterial engineering. Non-viral nanoparticles provide a clue to reducing drug price burdens by simplifying the high costs of viral vector production. The fact that repeated dosing routes can be flexibly designed according to patient status, without the concern of neutralizing antibody formation, is also positive.
However, barriers to clinical implementation remain clear. The chronic neurotoxicity and micro-inflammatory responses that synthetic polymers and nanomaterials may cause by remaining in the central nervous system for long periods must be rigorously evaluated. Primate preclinical trials are essential to verify whether the BBB permeability figures obtained in rodent models are reproducible in the complex human structure.
Establishing a uniform mass-synthesis process at the Good Manufacturing Practice (GMP) scale, which is essential for clinical entry, is also a key task. If long-term safety data is accumulated, the accessibility of treatment for severe patients, who have had to endure the pain of lifelong illness, is expected to expand significantly.
BACKGROUND: Spinal muscular atrophy (SMA) is a disorder characterized by the degeneration of lower motor neurons caused by mutations in the survival motor neuron 1 ( METHODS: This review article provides an overview of SMA, encompassing the characteristics of the disease, standard-of-care techniques, including respiratory care and physiotherapy, and existing treatments and recent advancements in novel therapeutic strategies and biomaterials for SMA. Several limitations associated with the existing SMA treatment methods are also discussed. RESULTS: The review highlights significant progress in SMA therapy, including gene replacement therapies, antisense oligonucleotides, and small-molecule drugs that enhance SMN protein production. Despite these advancements, current treatments face limitations related to delivery efficiency, cost, and long-term efficacy. Novel biomaterials and delivery systems show promise in overcoming these challenges and improving treatment outcomes. CONCLUSIONS: A deeper understanding of SMA pathophysiology has led to transformative therapeutic advances; however, challenges remain in optimizing treatment accessibility, durability, and safety. Continued research focusing on innovative therapeutic designs and biomaterial applications holds potential to further enhance the quality of life and prognosis for individuals with SMA.
If biomaterial platform technologies are applied clinically, the treatment environment will change significantly. Patients suffering from severe scoliosis could receive drugs via simple intravenous injections or semi-annual local hydrogel procedures instead of lumbar punctures that involve general anesthesia and extreme pain. This is a practical pathway to help patients and caregivers, who had to interrupt their education or professional lives due to frequent hospitalizations, return to daily life.
From a pharmaceutical industry perspective, the massive investment costs for viral vector production facilities can be significantly reduced. Synthetic nanomaterials facilitate the establishment of mass production processes, greatly lowering the unit price of finished drugs. This serves as a turning point to alleviate the pressure on national health insurance finances caused by drug prices reaching billions of won per patient, while simultaneously expanding treatment opportunities for patients who had to abandon medication due to the burden of treatment costs.